SMS Lifesciences India's Q2 FY 2025-26 Quarterly Results

Result Summary

• SMS Lifesciences India Ltd reported a 2.0% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 1.6%.
• Its expenses for the quarter were down by 4.1% QoQ and 3.3% YoY.
• The net profit increased 46.2% QoQ and increased 94.5% YoY.
• The earnings per share (EPS) of SMS Lifesciences India Ltd stood at 20.19 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

SMS Lifesciences India Ltd is a pharmaceutical company engaged in the development, manufacture, and sale of active pharmaceutical ingredients (APIs). The company's primary focus is on producing high-quality APIs used in various therapeutic areas. As a player in the pharmaceutical industry, SMS Lifesciences is involved in the research and development of new drug formulations, leveraging its manufacturing capabilities to support the global healthcare sector. The company is headquartered in India and has established a presence in both domestic and international markets. Any recent major developments or changes in the company's operations are not available from the current dataset.

Revenue

For the second quarter of the fiscal year 2026 (Q2FY26), SMS Lifesciences India Ltd reported a total income of ₹81.79 crores. This represents a slight decrease of 2.0% compared to the previous quarter (Q1FY26), which saw a total income of ₹83.50 crores. However, when compared year-over-year (YoY) to the second quarter of the previous fiscal year (Q2FY25), the total income increased by 1.6%, having been ₹80.50 crores in that period. The data indicates the company's ability to maintain a steady revenue stream despite short-term fluctuations on a quarterly basis.

Profitability

In the area of profitability, SMS Lifesciences India Ltd experienced significant growth. The company's profit before tax (PBT) for Q2FY26 was ₹8.49 crores, marking a 20.9% increase over the previous quarter and an 80.6% increase year-over-year from Q2FY25, where the PBT was ₹4.70 crores. The tax expense for Q2FY26 was ₹2.07 crores, a decrease of 21.6% from Q1FY26 and an increase of 47.9% compared to Q2FY25. Consequently, the profit after tax (PAT) for the quarter was ₹6.42 crores, reflecting a 46.2% increase quarter-over-quarter and a 94.5% increase year-over-year. The earnings per share (EPS) for Q2FY26 stood at ₹20.19, compared to ₹13.75 in Q1FY26 and ₹15.46 in Q2FY25, showcasing a strong growth trajectory in profitability metrics.

Operating Metrics

The financial data reveals that SMS Lifesciences India Ltd managed to reduce its total expenses significantly in Q2FY26 to ₹73.31 crores, down by 4.1% from ₹76.48 crores in Q1FY26 and a 3.3% decrease from ₹75.80 crores in Q2FY25. This controlled reduction in expenses contributed to the improved profit margins observed during the quarter. The company's ability to manage its operating costs effectively is reflected in the strong increase in both profit before and after tax, along with the notable rise in earnings per share. These metrics suggest efficient operational management in the face of fluctuating revenue streams.